were vaccinated with a trivalent inactivated virosomal influenza vaccine. Serum haemagglutinin inhibition antibody titres were determined for the three viral strains at the time of vaccination and 1 month later. CD4 cell counts and HIV viral loads were measured to evaluate the effect of vaccination on HIV status. Adverse reactions were monitored during the first hour following vaccination by an investigator and then on a continuous basis by the parents. Seroconversion rates against the three viral strains A/H3N2, A/H1N1 and B were 73.9%, 56.5% and 52.2%, respectively. Geometric mean antibody titres increased after 1 month compared with baseline values (A/H3N2: 70.9 versus 13.5; A/H1N1: 24.7 versus 5.8; B: 34.4 versus 9.1). No significant changes were observed in either HIV viral load or CD4 cell count following vaccination. Vaccination was well tolerated with only a few mild, transient symptoms.
Introduction
Children infected with the human immunodeficiency virus (HIV) have a greater risk of developing the complications associated with influenza infection than members of the healthy population; they often require admission to hospital and antibiotic treatment. 1 -3 The yearly infection rate in healthy children ranges from 10% to 40%, with an estimated risk of pulmonary complications between 0.2% and 25%. One per cent of infected children require hospital admission. 4 In HIV-infected children, the clinical features of influenza are similar to those observed in children without HIV. 5, 6 It should, however, be noted that there is an association between HIV infection status and the duration of disease. Airborne viral discharge lasts on average 14 days from symptom onset in HIV-negative children. 1 In contrast, HIVinfected children, particularly those with a low CD4 cell count, may discharge influenza virus for more than 9 weeks. 6, 7 A consequence of a longer period of infection may be an increased need to access either out-patient or in-patient medical care. For this reason, influenza vaccination may be recommended for HIV-infected patients, even if uncertainties still exist about the possible effect of immunosuppression (decreased CD4 cell count) or increased HIV viral load following vaccination. 8 The World Health Organization recommends, as one of the most important measures to reduce the impact of the disease, annual immunization of people at high risk of influenza infection. In healthy children, vaccine efficacy ranges from 70% to 80%, 9 but an impaired immune system due to HIV infection could affect both vaccine efficacy and tolerability.
We evaluated the efficacy, tolerability and the effects on CD4 cell count and HIV viral load of a trivalent inactivated virosomal influenza vaccine, in a cohort of HIV-infected children attending the Department of Paediatrics, San Paolo Hospital, Milan, Italy.
Patients and methods

STUDY POPULATION AND VACCINE ADMINISTRATION
In October 1999, children with vertically acquired HIV infection, followed from birth in the Paediatric Infectious Disease Unit of our hospital, were enrolled in the study. The children had not been vaccinated against influenza prior to the study. Demographic data, history of former influenza vaccination and information on health status were also collected for each child. The Department of Paediatrics' Ethics Committee approved the study design and written informed consent was obtained from the children's parents or tutors.
The children were vaccinated with a single dose of a trivalent virosome-adjuvanted influenza vaccine, licensed in Italy for the 1999 -2000 season (Inflexal ® V, Berna Biotech Ltd, Berne, Switzerland). The vaccine contained 15 µg surface haemagglutinin (HA) antigen from each of the strains: A/Sydney/5/97 (H3N2), A/Beijing/262/95 (H1N1), and B/Beijing/184/93 (B). The vaccine was stored between 2°C and 8°C and was brought to room temperature (23°C) 1 h before administration. Each patient received a single dose (0.5 ml) of vaccine by intramuscular injection in the zona glutea.
INFLUENZA ANTIBODY TITRE
Samples of serum were collected from each child immediately before vaccination and 1 month post-vaccination. All samples were frozen as quickly as possible and kept at -20°C until analysis. Antibody levels against the three different strains were determined by serum haemagglutination inhibition (HI), which was measured at the time of vaccination (T0) and 1 month postvaccination (T1). The HI antibody titres were evaluated according to the European Medicines Agency (EMEA) criteria 10 that have been defined for adults aged 18 -60 years, as there were no specific criteria for children.
Seroconversion was defined as a four-fold or greater increase in HI antibody titre and a titre of ≥ 1:40 reached in > 40% of subjects. Seroprotection was considered to have been achieved if a titre ≥ 1:40 was reached in > 70% of subjects.
CD4 CELL COUNT AND HIV VIRAL LOAD
The CD4 cell count was measured by flow cytometry (TriTEST, Becton Dickinson Company, North Canaan, CT, USA) at T0 and T1. The HIV-RNA viral load was measured using polymerase chain reaction (PCR Amplicor HIV-Monitor, Roche Diagnostics, Indianapolis, IN, USA) at T0, T1, 2 months after immunization (T2) and 3 months (T3) post-vaccination.
EVALUATION OF ADVERSE EFFECTS
The observer who examined the children for the first hour after vaccination evaluated all
TABLE 1: Seroconversion against three strains of influenza at 30 days post-vaccination in a cohort of HIV-infected children (n = 23) vaccinated with a trivalent virosomal influenza vaccine
Viral strain No. of children Percentage (%)
A/H3N2 17 73.9 A/H1N1 13 56.5 B 1 2 52.2
Antibody titres were evaluated according to European Medicines Agency criteria. 10 Seroconversion was defined as a four-fold or greater increase in antibody titre and a titre of ≥ 1:40 reached in > 40% of subjects.
adverse effects. Once the children were at home, the parent(s) continued the observations. Parents were provided with a form to record any adverse events related to vaccination and the general health status of their child. The children continued to be examined at monthly intervals as part of the care plan for HIV-infected children at our hospital.
STATISTICAL ANALYSIS
Personal records were entered in a database and processed using the SPSS statistical package 11.0 for Windows (SPSS Inc., Chicago, IL, USA 
Results
STUDY POPULATION
SAFETY ASSESSMENT
Three subjects (13%) reported adverse effects following vaccination. One child had pain at the injection site 24 h after the injection. Another child experienced a mild headache on the day following the injection, and fever was reported in one child (axillary temperature 38.5°C), which was treated with anti-pyretic agents. Table 2 ). The increases in the geometric mean antibody titre ranged from 5 to 6 ( Table 2) . A protective antibody titre (≥ 1:40) was reached in 82.6% of children for strain A/H3N2, in 56.5% for strain A/H1N1, and 60.9% for strain B (Table 3 ).
INFLUENZA ANTIBODY TITRE
CD4 COUNT AND HIV VIRAL LOAD
No statistically significant changes were observed in the mean CD4 cell counts between T0 and T1 (Table 4 ). There were no significant changes in viral load observed during the 3 months following vaccination, as shown in Table 5 . 
TABLE 3: Seroprotection against three strains of influenza at baseline (T0) and 30 days postvaccination (T1) in a cohort of HIV-infected children (n = 23) vaccinated with a trivalent virosomal influenza vaccine
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Discussion
Individuals with HIV-1 infection are at an increased risk of developing complications associated with influenza infection, for which vaccination is the most effective means of prevention. When considering the potential interaction between influenza vaccination and HIV infection, we can ask two questions: (i) Does HIV infection compromise the efficacy and tolerability of the influenza vaccine? (ii) Does vaccination influence the CD4 cell count and viral load, altering the natural history of HIV infection? Several case-controlled studies on influenza vaccination in HIV-infected patients reported increased protection against influenza, even if the immunological response was weaker than that observed in controls without HIV infection. 12 -17 Accordingly, influenza vaccination should be recommended in HIVinfected patients as it provides effective protection, 16,18 -21 although the effects of vaccination might be weaker than in HIVnegative patients. 13, 14 Seroprotection against influenza infection might lead to a reduction in hospital admissions and deaths in HIVinfected individuals. 1 Administration of an effective, welltolerated vaccine, such as a virosomeadjuvanted vaccine, in HIV-infected children might be helpful for reducing influenza infections. 22 A recent trial assessed the immunogenicity of two widely used influenza vaccines in healthy children: the virosome-adjuvanted influenza vaccine (Inflexal ® V, Berna Biotech Ltd); and a split influenza vaccine (Fluarix ® , GlaxoSmithKline Biologicals, Rixensart, Belgium). 23 In that study, subgroups of primed and unprimed children were compared. Primed children were only immunized on day 1, while unprimed children aged > 36 months were immunized with two doses of 0.5 ml on day 1 and day 29 ± 3. The humoral immunogenicity was assessed in primed children at baseline (as in all children) and 4 weeks after the vaccination, and in unprimed children at baseline and 4 weeks after the second vaccination. The study found that both vaccines fulfilled the EMEA criteria for seroconversion, seroprotection and increases in geometric mean titre for all three influenza strains. Both vaccines were also well tolerated. There was no statistically significant difference between the primed and unprimed children with one exception: in unprimed children, the seroconversion rate against strain A/H1N1 was higher after the virosome-adjuvanted vaccine (89%) than after the split influenza vaccine (78%; P = 0.021). 23 The geometric mean titre after vaccination increased for all three influenza strains examined in the study. 23 In unprimed children, the magnitude of the increase for the H1N1, H3N2 and B strains was about 27, 8 and 50 in the virosomal vaccine-treated group, respectively, and 18, 8 and 43 in the split vaccine-treated group, respectively. In primed children, the magnitude of the increase for the H1N1, H3N2 and B strains was 6, 5 and 16 in the virosomal vaccinetreated group, respectively, and 11, 4 and 23 in the split vaccine-treated group, respectively.
In the unprimed HIV-infected children examined in our study, the magnitude of the increase in the geometric mean titres for the H1N1, H3N2 and B strains was 5, 6 and 5, respectively. These results are in part comparable with the primed healthy children who received only one dose in the study by Kanra et al. 23 It may be GV Zuccotti, A Zenga, P Durando et al.
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hypothesized that the HIV status led to a prior immunization with influenza virus during previous flu seasons, and this may further reduce the effectiveness of vaccinations, as has been suggested by other authors. 13, 14 The fact that the majority of the children in our study achieved protective antibody titres may be, at least in part, due to their good immunological status. Nearly all of the children were classified as CDC class 1, an immunological status closely associated with anti-retroviral therapy. Children in the first stages of HIV infection achieve protective antibody titres more easily than children in the advanced stages of infection. 7, 21, 24 Individuals with CD4 cell counts ≥ 200 cells/mm 3 develop significantly higher antibody titres than patients with CD4 cell counts < 200 cells/mm 3 . 25, 26 The study by Kanra et al. 23 showed that in the group of children immunized with the virosome-adjuvanted vaccine, seroconversion and seroprotection rates for the three influenza strains (H1N1, H3N2, B) were as follows: seroconversion, 55%, 55% and 78% in the primed group, respectively, and 89%, 70% and 95% in the unprimed group, respectively; seroprotection, 85%, 88% and 78% in the primed group, respectively, and 89%, 78% and 95% in the unprimed group, respectively. In our study, the corresponding rates were: seroconversion, 57%, 74% and 52%, respectively; and seroprotection, 57%, 83% and 61%, respectively. The slightly lower seroprotection rates observed in the HIVinfected children in our study were not unexpected, as HIV-infected children have impaired immune responses.
Influenza infection in HIV-infected children frequently induces an increase in HIV viral load with a diminution of CD4 cell counts 18 and the same might occur in the case of vaccination against influenza. The influence of vaccination on the natural history of HIV infection has been debated in the published literature. Initially, authors agreed that influenza vaccination leads to increased viral loads (HIV-RNA) and decreased CD4 lymphocyte counts in HIVinfected children and adults, 16, 18, 19, 26 but possibly only in a transitory way. 14, 25 Recent studies in HIV-infected adults do not confirm these hypotheses, 16,18, 26 -30 and in our study, we did not detect any significant change in CD4 cell counts before vaccination and 1 month later. There were also no significant changes in the viral load during the 3 months following vaccination. These findings were consistent with the published literature.
The tolerability of a trivalent virosomal influenza vaccine in HIV-infected children was good, with only three mild transitory adverse events reported. Only one patient experienced pain at the injection site, which was attributable to the vaccine.
Owing to the design, this study was not able to establish whether administration of virosome-adjuvanted influenza vaccine exhibits a better effect compared with alternative influenza vaccines. Within the limitations of this study, and based on the results, it can be concluded that virosomeadjuvanted influenza vaccine was immunogenic and well tolerated in HIV-infected children, however. In addition, vaccination of HIV-infected children with virosomeadjuvanted influenza vaccine had no effect on CD4 cell count or HIV viral load.
